Phase I/II study of Nivolumab + Ipilimumab followed by Nivolumab + dose escalated Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas after one prior line of chemotherapy
Brief description of study
If you have been diagnosed with metastatic sarcoma that has progressed after standard treatment, you may qualify for this Phase I/II study. The main goal of this study effectiveness and the side effects of the combination of two agents nivolumab and ipilimumab, followed by the combination of nivolumab and a third agent, pazopanib.
Clinical Study Identifier: s16-02078
ClinicalTrials.gov Identifier: NCTs16-02078
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
